Roche Holding AG has announced its intent to acquire 89bio Inc. for up to $3.5 billion, expanding its presence in the rapidly growing market for liver and cardiometabolic disorders and positioning the company to capitalize on the demand for innovati…

Roche Holding AG has announced its intention to acquire 89bio Inc., a biopharmaceutical company specializing in liver and metabolic disorders, in a deal valued at up to $3.5 billion.

89Bio, Inc. faces financial challenges and uncertain future prospects despite its focused mission to develop treatments for liver and metabolic disorders.

89Bio Inc.’s stock price has seen fluctuations, with a recent target price adjustment to $55 by Cantor Fitzgerald, amidst the company’s focus on liver and metabolic disorder treatments.